How AI Chatbots Became Pharma’s Newest Promotional Risk
Every time ChatGPT answers a drug question, it may be doing something no FDA-approved ad campaign ever could — and […]
Every time ChatGPT answers a drug question, it may be doing something no FDA-approved ad campaign ever could — and […]
Scroll through enough patient forums and a pattern emerges: people aren’t just asking about side effects—they’re experimenting in real time.
There’s a certain genre of drug question that never goes out of style. It sits somewhere between wishful thinking and
The standard pharmacovigilance process has a timing problem Adverse events travel faster than case reports. A patient posts about a
Spend enough time in the DrugChatter logs and a pattern emerges. It’s not pharmacology. It’s not even really medicine. It’s
If you want to understand a drug, don’t start with the label—start with the questions people ask at 2 a.m.
There’s a particular genre of drug question that never goes out of style: “What happens if I mess this up?”
There’s a pattern to mass adoption in pharma. First comes clinical data, then prescriber uptake, then—inevitably—the public internet asking the
While DrugChatter is a specialized platform for medication discussions, many of the most surprising side effects surfaced by its users
Every morning, thousands of pharmaceutical field reps walk into physician offices carrying approved messaging, printed leave-behinds, and CRM notes from
Summary:Patient interest clusters heavily around drug–drug interactions, food effects, and therapeutic alternatives. Statins (especially Lipitor), biologics like Cosentyx, and common
By the time your next drug launches, a chatbot will already have an opinion about it — and 40 million
Get sharp analysis on AI-generated drug information, off-label curiosity, pharmacovigilance blind spots, and the shifting intersection of pharma, search, and large language models. No fluff. Just the signals that matter.